News

Michael T. Tees, MD, discusses chimeric antigen receptor T-cell therapies, including ALLO-501A, and its use for patients with relapsed or refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Neal D. Shore, MD, FACS, gave an overview of previous and updated findings from the ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer.

With a plethora of chemotherapy agents currently unavailable for patients with solid tumors and hematologic malignancies, experts are calling for the FDA and pharmaceutical companies to make important changes.

Data from an analysis of the combined NRG-RTOG 0630/9514 trials show that pathologic complete response can be used as a prognostic factor for clinical outcomes in future research of patients with soft tissue sarcoma.

In a prospective effectiveness trial, care delivered to patients with lung cancer using a multidisciplinary model was compared with care delivered at a traditional serial care model.

Enfortumab vedotin plus pembrolizumab is now an FDA approved treatment based on positive phase 1b/2 findings.

Soon, the FDA will be considering fruquintinib for approval to treat patients with refractory metastatic colorectal cancer.

The next-generation anthracycline Annamycin has been administered to the first patient with relapsed/refractory acute myeloid leukemia in combination with cytarabine in a phase 1/2 study.

David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of larotrectinib for patients with solid tumors who harbor an NTRK fusion.

The addition of eftilagimod alpha to pembrolizumab in patients with PD-1 resistant non–small cell lung cancer led to tumor shrinkage.

Here is a look back at the FDA happenings from March 2023.

According to a phase 1b study, ibrutinib can modulate immune response and lead to some promising immune effects for patients with metastatic pancreatic ductal adenocarcinoma.

Lajos Pusztai, MD, DPhil, discusses the methods and design of the phase 3 KEYNOTE-522 trial.

Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.

Recent successes have been observed for patients with locally advanced, unresectable non–small cell lung cancer regarding new treatment options.

After 3 years of follow-up in the ZUMA-5 trial, patients with relapsed/refractory indolent non-Hodgkin lymphoma treated with axicabtagene ciloleucel had durable responses.

Cary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.

At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.

Qian Wang, MD, MPH, discusses the changing incidence of small cell lung cancer among patients globally and in the United States.

A phase 1/2 trial investigating GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas will begin following the acceptance of an investigational new drug application for the agent.

Based on findings from a phase 1 trial, osemitamab has gained an orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

One of the key tools used to detect leukemic cells is measurable residual disease, formerly referred to as minimal residual disease.

Debu Tripathy, MD, discusses the TBCRC049 study which evaluated tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.

Ken Kato, MD, PhD, discusses which patient characteristics to look out for when looking to put a patient on the combination of ipilimumab and nivolumab.

The FDA has granted a fast-track designation for RRx-001 and accepted the investigational new drug application for a phase 2b trial of severe oral mucositis in chemotherapy- and radiation-treated patients with head & neck cancer.

Matthew P. Goetz, MD, discusses the next steps for evaluating treatment with lasofoxifene.

New results from the phase 2 APPLE trial shows how the use of osimertinib in the upfront setting compares with combination therapy in patients with EGFR-positive non–small cell lung cancer.

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, discussed the currently approved JAK inhibitors used to treat patients with myelofibrosis, and exciting movements in the field.

Courtney D. DiNardo, MD, MSCE, provided an overview of venetoclax resistance and interrelated mechanisms, with a spotlight on kinase signaling pathways, TP53 mutation, monocytic, and other forms of resistance.

A full approval has been granted to pembrolizumab by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors.